SGK1 as a therapeutic target for central nervous system diseases.
- Author:
Ya-Kang XING
1
;
Wei LUO
1
;
Meng-Yao FAN
1
;
Ya-Wei TAN
1
;
Xiao LI
2
Author Information
1. College of Basic Medical Sciences, Gannan Medical University, Ganzhou 341000, China.
2. College of Basic Medical Sciences, Gannan Medical University, Ganzhou 341000, China. 18970786303@gmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Cell Proliferation;
Central Nervous System Diseases/drug therapy*;
Inflammation;
Protein Serine-Threonine Kinases/physiology*
- From:
Acta Physiologica Sinica
2023;75(3):451-464
- CountryChina
- Language:Chinese
-
Abstract:
Serum and glucocorticoid-regulated kinase 1 (SGK1) plays an important role in the physiological processes of hormone release, neuronal excitation and cell proliferation. SGK1 also participates in the pathophysiological processes of inflammation and apoptosis in the central nervous system (CNS). Increasing evidence demonstrates that SGK1 may serve as a target of the intervention of neurodegenerative diseases. In this article, we summarize the recent progress on the role and molecular mechanisms of SGK1 in the regulation of the function of the CNS. We also discuss the potential of newly discovered SGK1 inhibitors in the treatment of CNS diseases.
